Skip to main content

Advertisement

Table 2 Neutralizing antibody titers of mice injected once with the vaccine and virus titers in the lungs after challenge

From: Potency of a vaccine prepared from A/swine/Hokkaido/2/1981 (H1N1) against A/Narita/1/2009 (H1N1) pandemic influenza virus strain

Vaccine NT titer to Virus titer in lungs, mean log PFU/g ±Sea
Strain Protein, μg Formulation Narita/09 Sw/Hok/81  
PBS - - <10, <10, <10, <10, <10 <10, <10, <10, <10, <10 5.0±0.17
Narita/09 4 ES <10, <10, <10, <10, <10 ND 4.6±0.10
  20 ES <10, 20, 20, 20, 40 ND 4.6±0.12
  100 ES 20, 40, 80, 160, 160 ND 4.1±0.35
Narita/09 4 WV 40, 40, 40, 80, 160 ND 4.2±0.17
  20 WV 40, 80, 160, 160, 320 ND 3.9±0.25*
  100 WV 320, 320, 640, 1280, 1280 ND 2.4±0.50**
Sw/Hok/81 4 ES <10, <10, <10, <10, <10 <10, <10, <10, 10, 10 4.6±0.04
  20 ES <10, <10, <10, <10, <10 <10, 10, 10, 20, 80 4.4±0.02
  100 ES <10, <10, <10, <10, <10 10, 20, 20, 40, 40 4.7±0.02
Sw/Hok/81 4 WV <10, <10, <10, <10, <10 20, 40, 40, 40, 80 4.5±0.06
  20 WV <10, <10, <10, <10, <10 20, 40, 80, 80, 80 4.4±0.04
  100 WV <10, <10, <10, <10, <10 160, 160, 160, 160, 320 4.3±0.09
  1. Mice were injected with each vaccine subcutaneously. Serum samples were collected 3 weeks after injection.
  2. The animals were challenged by intranasal administration of 106.0 PFU of A/Narita/09.
  3. At 3 days after challenge, lungs samples were collected and virus titers were measured. ES: ether split vaccine, WV: whole inactivated vaccine
  4. a: Data are for 5 mice.
  5. *: P<0.05, vs. virus titers in PBS group.
  6. **: P<0.01, vs. virus titers in PBS group.